{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:00:41Z","timestamp":1789617641867,"version":"build-2803163510"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.imlet.2014.01.014","type":"journal-article","created":{"date-parts":[[2014,2,2]],"date-time":"2014-02-02T17:01:39Z","timestamp":1391360499000},"page":"163-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome"],"prefix":"10.1016","volume":"160","author":[{"given":"Mih\u00e1ly","family":"J\u00f3zsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Nozal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"L\u00f3pez-Trascasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"S\u00e1nchez-Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Proh\u00e1szka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Uzonyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2014.01.014_bib0005","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.it.2008.11.003","article-title":"Complement activation and inhibition: a delicate balance","volume":"30","author":"Sj\u00f6berg","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0015","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.1203487","article-title":"Complement in immune and inflammatory disorders: pathophysiological mechanisms","volume":"190","author":"Ricklin","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.molimm.2013.05.009","article-title":"Autoantibodies against complement components and functional consequences","volume":"56","author":"Dragon-Durey","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0025","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2249.2007.03574.x","article-title":"Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals","volume":"151","author":"Pickering","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0030","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/j.molimm.2009.05.018","article-title":"Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles","volume":"46","author":"Skerka","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0035","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.imlet.2014.01.014_bib0040","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.imlet.2014.01.014_bib0045","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/ki.1989.61","article-title":"Antibody to a cryptic, solid phase C1Q antigen in membranoproliferative nephritis","volume":"35","author":"Strife","year":"1989","journal-title":"Kidney Int"},{"key":"10.1016\/j.imlet.2014.01.014_bib0050","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/S0022-3476(05)82710-6","article-title":"Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis","volume":"116","author":"Strife","year":"1990","journal-title":"J Pediatr"},{"key":"10.1016\/j.imlet.2014.01.014_bib0055","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.molimm.2010.02.002","article-title":"Anti-factor, B autoantibody in dense deposit disease","volume":"47","author":"Strobel","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0060","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.164.3878.436","article-title":"Serum C\u20193 lytic system in patients with glomerulonephritis","volume":"164","author":"Spitzer","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.imlet.2014.01.014_bib0065","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-1229(90)90018-L","article-title":"Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis","volume":"57","author":"Spitzer","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0070","first-page":"33","article-title":"Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor","volume":"43","author":"Daha","year":"1981","journal-title":"Immunology"},{"key":"10.1016\/j.imlet.2014.01.014_bib0075","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0090-1229(89)90141-4","article-title":"A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III","volume":"50","author":"Clardy","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0080","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0090-1229(90)90144-F","article-title":"Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF","volume":"56","author":"Tanuma","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.116.1.1","article-title":"C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase","volume":"116","author":"Daha","year":"1976","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0090","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1073\/pnas.73.9.3268","article-title":"Control of the amplification convertase of complement by the plasma protein beta1H","volume":"73","author":"Weiler","year":"1976","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.imlet.2014.01.014_bib0095","first-page":"449","article-title":"Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor","volume":"68","author":"Ito","year":"1989","journal-title":"Immunology"},{"key":"10.1016\/j.imlet.2014.01.014_bib0100","first-page":"209","article-title":"Regulation of the C3 nephritic factor stabilized C3\/C5 convertase of complement by purified human erythrocyte C3b receptor","volume":"50","author":"Daha","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2249.1992.tb06984.x","article-title":"Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN)","volume":"89","author":"Ohi","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0110","doi-asserted-by":"crossref","unstructured":"Paix\u00e3o-Cavalcante D, L\u00f3pez-Trascasa M, Skattum L, Giclas PC, Goodship TH, Rodr\u00edgez de C\u00f3rdoba S, et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int 2012;82:1084\u201392.","DOI":"10.1038\/ki.2012.250"},{"key":"10.1016\/j.imlet.2014.01.014_bib0115","first-page":"73","article-title":"Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro","volume":"65","author":"Mollnes","year":"1986","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0120","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1681\/ASN.2007030356","article-title":"New approaches to the treatment of dense deposit disease","volume":"18","author":"Smith","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0125","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1034\/j.1399-3038.2001.012003166.x","article-title":"Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up","volume":"12","author":"Schwertz","year":"2001","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0130","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1681\/ASN.2005010078","article-title":"Membranoproliferative glomerulonephritis type II (dense deposit disease): an update","volume":"16","author":"Appel","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jmg.2006.045328","article-title":"Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome","volume":"44","author":"Servais","year":"2007","journal-title":"J Med Genet"},{"key":"10.1016\/j.imlet.2014.01.014_bib0140","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1084\/jem.177.6.1827","article-title":"Complement-mediated adipocyte lysis by nephritic factor sera","volume":"177","author":"Mathieson","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.imlet.2014.01.014_bib0145","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM197602262940902","article-title":"The complement abnormalities of lipodystrophy","volume":"294","author":"Sissons","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imlet.2014.01.014_bib0150","first-page":"609","article-title":"C3 nephritic factor and SLE: report of four cases and review of the literature","volume":"87","author":"Walport","year":"1994","journal-title":"Q J Med"},{"key":"10.1016\/j.imlet.2014.01.014_bib0155","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0022-3476(05)82711-8","article-title":"Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event","volume":"116","author":"Spitzer","year":"1990","journal-title":"J Pediatr"},{"key":"10.1016\/j.imlet.2014.01.014_bib0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0090-1229(92)90197-V","article-title":"On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production","volume":"64","author":"Spitzer","year":"1992","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0022-1759(87)90438-8","article-title":"C3 nephritic factor determination. A comparison between two methods","volume":"98","author":"L\u00f3pez-Trascasa","year":"1987","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.imlet.2014.01.014_bib0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0022-1759(82)90386-6","article-title":"A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes","volume":"51","author":"Rother","year":"1982","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.imlet.2014.01.014_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2007.12.001","article-title":"A hemolytic method for the measurement of nephritic factor","volume":"335","author":"West","year":"2008","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.imlet.2014.01.014_bib0180","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0022-1759(87)90421-2","article-title":"Quantitation of C3 nephritic factor of alternative complement pathway by an enzyme-linked immunosorbent assay","volume":"105","author":"Seino","year":"1987","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.imlet.2014.01.014_bib0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2215\/CJN.07900811","article-title":"Causes of alternative pathway dysregulation in dense deposit disease","volume":"7","author":"Zhang","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0190","first-page":"82","article-title":"C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis","volume":"76","author":"Tanuma","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0195","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2249.1994.tb06530.x","article-title":"Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN)","volume":"95","author":"Ohi","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00467-010-1734-4","article-title":"Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation","volume":"26","author":"Leroy","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0205","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/ajkd.2001.24511","article-title":"Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2","volume":"37","author":"West","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.imlet.2014.01.014_bib0210","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1172\/JCI109787","article-title":"Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme","volume":"65","author":"Halbwachs","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1016\/j.imlet.2014.01.014_bib0215","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.4049\/jimmunol.125.5.2051","article-title":"Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein","volume":"125","author":"Daha","year":"1980","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.154.1.1","article-title":"Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase","volume":"154","author":"Gigli","year":"1981","journal-title":"J Exp Med"},{"key":"10.1016\/j.imlet.2014.01.014_bib0225","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/eji.1830141209","article-title":"Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor","volume":"14","author":"Fischer","year":"1984","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0230","first-page":"65","article-title":"C4 nephritic factor in a patient with chronic glomerulonephritis","volume":"22","author":"Fujita","year":"1987","journal-title":"J Clin Lab Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0235","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0022-1759(90)90468-B","article-title":"Quantitation of C4 nephritic factor by an enzyme-linked immunosorbent assay","volume":"128","author":"Seino","year":"1990","journal-title":"Immunol Methods"},{"key":"10.1016\/j.imlet.2014.01.014_bib0240","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1056\/NEJMc1107484","article-title":"Combined C3b and factor B autoantibodies and MPGN type II","volume":"365","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imlet.2014.01.014_bib0245","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1084\/jem.175.4.939","article-title":"Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis","volume":"175","author":"Meri","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.imlet.2014.01.014_bib0250","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.4049\/jimmunol.163.8.4590","article-title":"Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H","volume":"163","author":"Jokiranta","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0255","doi-asserted-by":"crossref","unstructured":"Nozal P, Strobel S, Ibernon M, L\u00f3pez D, S\u00e1nchez-Corral P, Rodr\u00edguez de C\u00f3rdoba S, et al. Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. Clin Kidney J 2012;5:133\u20136.","DOI":"10.1093\/ckj\/sfs002"},{"key":"10.1016\/j.imlet.2014.01.014_bib0260","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molimm.2012.05.009","article-title":"Factor H autoantibodies in membranoproliferative glomerulonephritis","volume":"52","author":"Goodship","year":"2012","journal-title":"Mol Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0265","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2215\/CJN.07110810","article-title":"Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement","volume":"6","author":"Sethi","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0270","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: a case series","volume":"62","author":"Zand","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.imlet.2014.01.014_bib0275","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0280","doi-asserted-by":"crossref","unstructured":"J\u00f3zsi M, Zipfel PF. Factor H family proteins and human diseases. Trends Immunol 2008;29:380\u20137.","DOI":"10.1016\/j.it.2008.04.008"},{"key":"10.1016\/j.imlet.2014.01.014_bib0285","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0290","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2215\/CJN.05750611","article-title":"Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon","volume":"7","author":"Kavanagh","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0295","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","article-title":"Standardisation of the factor H autoantibody assay","volume":"219","author":"Watson","year":"2014","journal-title":"Immunobiology"},{"key":"10.1016\/j.imlet.2014.01.014_bib0300","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-1-62703-724-2_20","article-title":"Anti-factor h autoantibodies assay","volume":"1100","author":"Dragon-Durey","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0305","series-title":"Autoantibodies: detection, pathogenicity and health implications","first-page":"37","article-title":"Anti-factor H autoantibodies in kidney disease: detection, pathogenic role and relevance for treatment","author":"J\u00f3zsi","year":"2012"},{"key":"10.1016\/j.imlet.2014.01.014_bib0310","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2011.152","article-title":"Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome","volume":"80","author":"Strobel","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.imlet.2014.01.014_bib0315","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/ndt\/gfp388","article-title":"Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome","volume":"25","author":"Strobel","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.imlet.2014.01.014_bib0320","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0325","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.1200679","article-title":"Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome","volume":"189","author":"Blanc","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0330","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.molimm.2013.11.021","article-title":"An ELISA assay with two monoclonal antibodies allows the estimation of free Factor H and identifies patients with acquired deficiency of this complement regulator","volume":"58","author":"Nozal","year":"2014","journal-title":"Mol Immunol"},{"issue":"October","key":"10.1016\/j.imlet.2014.01.014_bib0335","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","author":"Sinha","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.imlet.2014.01.014_bib0340","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","article-title":"Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency","volume":"111","author":"J\u00f3zsi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2014.01.014_bib0345","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2014.01.014_bib0350","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2215\/CJN.01260212","article-title":"Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome","volume":"8","author":"Hofer","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0355","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jmg.2008.064766","article-title":"The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome","volume":"46","author":"Dragon-Durey","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.imlet.2014.01.014_bib0360","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2009-05-223834","article-title":"Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome","volume":"114","author":"Abarrategui-Garrido","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2014.01.014_bib0365","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2007-02-071472","article-title":"Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome","volume":"110","author":"J\u00f3zsi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2014.01.014_bib0370","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.4049\/jimmunol.1200357","article-title":"Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3","volume":"189","author":"Kopp","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0375","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/j.ajkd.2009.12.026","article-title":"Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies","volume":"55","author":"Boyer","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"October","key":"10.1016\/j.imlet.2014.01.014_bib0380","article-title":"The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies","author":"Kim","year":"2013","journal-title":"Clin Nephrol"},{"issue":"January","key":"10.1016\/j.imlet.2014.01.014_bib0385","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00467-013-2558-9","article-title":"Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses","volume":"29","author":"Sana","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0390","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/ndt\/gfn063","article-title":"Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome","volume":"23","author":"Kwon","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.imlet.2014.01.014_bib0395","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1600-6143.2009.02586.x","article-title":"Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome","volume":"9","author":"Le Quintrec","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.imlet.2014.01.014_bib0400","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imlet.2014.01.014_bib0405","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1600-6143.2011.03923.x","article-title":"Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies","volume":"12","author":"McCaughan","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.imlet.2014.01.014_bib0410","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMc1112273","article-title":"Eculizumab in a patient with dense-deposit disease","volume":"366","author":"Daina","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imlet.2014.01.014_bib0415","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMc1111953","article-title":"Eculizumab for the treatment of dense-deposit disease","volume":"366","author":"Vivarelli","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imlet.2014.01.014_bib0420","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"November","key":"10.1016\/j.imlet.2014.01.014_bib0425","article-title":"Successful treatment of DEAP-HUS with eculizumab","author":"Noone","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0430","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.molimm.2013.05.224","article-title":"Complement therapy in atypical haemolytic uraemic syndrome (aHUS)","volume":"56","author":"Wong","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0435","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pep.2010.12.002","article-title":"Production of biologically active complement factor H in therapeutically useful quantities","volume":"76","author":"Schmidt","year":"2011","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.imlet.2014.01.014_bib0440","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.4049\/jimmunol.1203548","article-title":"Rational engineering of a minimized immune inhibitor with unique triple-targeting properties","volume":"190","author":"Schmidt","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2014.01.014_bib0445","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4049\/jimmunol.1300269","article-title":"An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H","volume":"191","author":"Hebecker","year":"2013","journal-title":"J Immunol"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247814000182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247814000182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T06:06:41Z","timestamp":1688969201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247814000182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0165247814000182"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2014.01.014","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2014.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}